David Debono
Overview
Explore the profile of David Debono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ukert B, Schauder S, Cullen D, Debono D, Eleff M, Fisch M
Am J Manag Care
. 2024 Oct;
30(10):494-499.
PMID: 39467179
Objective: Prior authorization is used to ensure providers treat patients with medically accepted treatments. Our objective was to evaluate prior authorization decisions in cancer care by race/ethnicity for commercially insured ...
2.
Mullangi S, Ukert B, DeVries A, Debono D, Santos J, Fisch M, et al.
J Clin Oncol
. 2024 Oct;
43(2):133-142.
PMID: 39356984
Purpose: The Oncology Care Model (OCM), a value-based payment model for traditional Medicare beneficiaries with cancer, yielded total spending reductions that were outweighed by incentive payments, resulting in net losses...
3.
Kanter G, Ozluk P, Chi W, Fisch M, Debono D, Parikh R, et al.
JAMA Netw Open
. 2024 May;
7(5):e2412998.
PMID: 38780938
Importance: Integration of pharmacies with physician practices, also known as medically integrated dispensing, is increasing in oncology. However, little is known about how this integration affects drug use, expenditures, medication...
4.
Parikh R, Civelek Y, Ozluk P, Debono D, Fisch M, Sylwestrzak G, et al.
Am J Manag Care
. 2024 Apr;
30(4):186-190.
PMID: 38603533
Objective: To assess the association between the onset of the COVID-19 pandemic and change in low-value cancer services. Study Design: In this retrospective cohort study, we used administrative claims from...
5.
Pham T, Gordon A, Chen X, Debono D, Fisch M
Cancer Treat Res Commun
. 2023 Oct;
37:100769.
PMID: 37839181
Introduction: Little is known about the effectiveness of immunotherapy alone or with chemotherapy for patients with non-small cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) expression <50 %....
6.
Liu Y, Mullangi S, Debono D, Chen X, Pham T, Fisch M, et al.
JCO Oncol Pract
. 2023 Jun;
19(9):731-740.
PMID: 37384847
Purpose: This retrospective observational study compared cancer care toxicity and cost outcomes for patients with metastatic cancer with nine different cancer types prescribed on- versus off-pathway regimens. Methods: This study...
7.
Mullangi S, Chen X, Pham T, Liu Y, Gordon A, Debono D, et al.
JAMA Netw Open
. 2023 May;
6(5):e2312461.
PMID: 37159199
Importance: Payers use oncology clinical pathways programs to increase evidence-based drug prescribing and control drug spending. However, compliance with these programs has been low, which may decrease their efficacy, and...
8.
Kanter G, Parikh R, Fisch M, Debono D, Bekelman J, Xu Y, et al.
JCO Oncol Pract
. 2022 Jul;
18(10):e1672-e1682.
PMID: 35830621
Purpose: The integration of pharmacies with oncology practices-known as medically integrated dispensing or in-office dispensing-could improve care coordination but may incentivize overprescribing or inappropriate prescribing. Because little is known about...
9.
Gunturu K, Pham T, Shambhu S, Fisch M, Barron J, Debono D
Support Care Cancer
. 2022 Jan;
30(5):4019-4026.
PMID: 35064328
Background: Immune checkpoint inhibitors (ICI) are increasingly used across multiple cancer types and stages and little is known about real-world outcomes. This study sought to determine healthcare utilization, costs, immune-related...
10.
Stephenson J, Gable J, Zincavage R, Price G, Churchill C, Zhu E, et al.
Patient Prefer Adherence
. 2021 Nov;
15:2417-2429.
PMID: 34764640
Purpose: To describe patients' perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i's) to treat metastatic breast cancer (MBC)....